| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Revenue-Product | 11.242 | - | - | - |
| Revenues | - | - | - | 10 |
| Cost of sales - product | 1.67 | - | - | - |
| Research and development expense | - | - | 24.754 | 18.062 |
| Cost of sales - intangible amortization | 0.29 | - | - | - |
| Selling, general and administrative expense | - | - | 12.276 | 10.215 |
| Research and development expenses | 28.412 | - | - | - |
| Operating expenses | - | - | 37.03 | 28.277 |
| Commercial expenses | 9.594 | - | - | - |
| Operating income (loss) | - | - | -37.03 | -18.277 |
| Medical affairs expenses | 3.047 | - | - | - |
| General and administrative expenses | 6.764 | - | - | - |
| Stock-based compensation expense | 2.178 | - | - | - |
| Depreciation expense | 0.002 | - | - | - |
| Interest income | 1.182 | - | - | - |
| Interest expense | 0.319 | - | 1.148 | 1.138 |
| Other nonoperating income (expenses) | - | - | -0.077 | -0.024 |
| Change in fair value of warrant liability | 55.881 | - | - | - |
| Investment income, interest | - | - | 0.831 | 0.983 |
| Change in fair value of notes | 2.748 | - | - | - |
| Amount of income (loss) from change in value of preferred stock tranche liability | - | - | - | 10.2 |
| Fair value adjustment of warrants | - | - | -13.457 | - |
| Other segment items | 0.037 | - | - | - |
| Net loss | -98.518 | -25.934 | -23.967 | -8.256 |
| Other comprehensive income (loss), available-for-sale securities adjustment, net of tax, portion attributable to parent | - | - | - | 0.004 |
| Change in fair value of notes attributable to instrument specific credit risk | -2.745 | -1.349 | - | - |
| Comprehensive loss | -95.773 | -24.585 | -23.967 | -8.252 |
| Earnings per share, basic | -1.35 | -0.39 | -0.6 | -0.31 |
| Earnings per share, diluted | -1.35 | -0.62 | -0.6 | -0.31 |
| Weighted average number of shares outstanding, basic | 73,157,000 | 66,143,000 | 40,258,000 | 26,861,000 |
| Weighted average number of shares outstanding, diluted | 73,157,000 | 74,037,000 | 40,258,000 | - |
Verastem, Inc. (VSTM)
Verastem, Inc. (VSTM)